Concepedia

Nathan Heald

NH

4

Publications

233

Citations

4

H-Index

2012

Active since

Affiliations

Exelixis (United States)(Current)

Nathan Heald is an author at Exelixis (United States) specializing in drug discovery, medicinal chemistry, and pharmacotherapy.

Top concepts

Publications per year

2012–2015

4

Publications

4

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 129 citations · Full text

Discovery of a Novel Series of Potent and Orally Bioavailable Phosphoinositide 3-Kinase γ Inhibitors

James W. Leahy, Chris A. Buhr, Henry W. B. Johnson et al. · Journal of Medicinal Chemistry · 2012 · 44 citations · Full text

, , +23

Quantitative Assessment of Antibody Internalization with Novel Monoclonal Antibodies against Alexa Fluorophores

Sindy Liao-Chan, Barbara Daine-Matsuoka, Nathan Heald et al. · PLoS ONE · 2015 · 39 citations · Full text

Discovery of a Novel Class of Potent and Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists

Mohamed A. Ibrahim, Henry W. B. Johnson, Joon Won Jeong et al. · Journal of Medicinal Chemistry · 2012 · 21 citations · Full text

, , +17

Rows per page

1–4 of 4